142 related articles for article (PubMed ID: 16432864)
1. Successful rapid discontinuation of immunosuppressive therapy at molecular relapse after allogeneic bone marrow transplantation in a pediatric patient with myelodysplastic syndrome.
Tamura K; Kanazawa T; Suzuki M; Koitabashi M; Ogawa C; Morikawa A
Am J Hematol; 2006 Feb; 81(2):139-41. PubMed ID: 16432864
[TBL] [Abstract][Full Text] [Related]
2. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
[TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
4. Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogenic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay.
Ogawa H; Tsuboi A; Oji Y; Tamaki H; Soma T; Inoue K; Sugiyama H
Bone Marrow Transplant; 1998 Mar; 21(5):525-7. PubMed ID: 9535047
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
[TBL] [Abstract][Full Text] [Related]
6. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
7. Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation.
Rautenberg C; Pechtel S; Hildebrandt B; Betz B; Dienst A; Nachtkamp K; Kondakci M; Geyh S; Wieczorek D; Haas R; Germing U; Kobbe G; Schroeder T
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2337-2343. PubMed ID: 29753838
[TBL] [Abstract][Full Text] [Related]
8. Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia.
Osborne D; Frost L; Tobal K; Liu Yin JA
Bone Marrow Transplant; 2005 Jul; 36(1):67-70. PubMed ID: 15908982
[TBL] [Abstract][Full Text] [Related]
9. Successful peripheral blood stem cell transplantation for myelodysplastic syndrome.
Ashihara E; Shimazaki C; Okamoto A; Shimura K; Takahashi R; Sumikuma T; Hirai H; Inaba T; Fujita N; Nakagawa M
Bone Marrow Transplant; 1999 Dec; 24(12):1343-5. PubMed ID: 10627645
[TBL] [Abstract][Full Text] [Related]
10. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?
Bader P; Niemeyer C; Weber G; Coliva T; Rossi V; Kreyenberg H; Gerecke A; Biondi A
Eur J Haematol; 2004 Jul; 73(1):25-8. PubMed ID: 15182334
[TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
[TBL] [Abstract][Full Text] [Related]
12. [Clinical implication of minimal residue disease monitoring by WT1 gene detection and flow cytometry in myelodysplastic syndrome with allogeneic stem cell transplantation].
Zhao XS; Mo XD; Hong Y; Chang YJ; Qin YZ; Liu YR; Chen YY; Zhang XH; Xu LP; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):998-1003. PubMed ID: 30612401
[No Abstract] [Full Text] [Related]
13. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
14. Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation.
Tajima K; Amakawa R; Uehira K; Matsumoto N; Shimizu T; Miyazaki Y; Fujimoto M; Kishimoto Y; Fukuhara S
Int J Hematol; 2000 Apr; 71(3):290-3. PubMed ID: 10846838
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
16. Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes.
Yoon JH; Jeon YW; Yahng SA; Shin SH; Lee SE; Cho BS; Lee DG; Eom KS; Kim HJ; Lee S; Min CK; Cho SG; Kim Y; Kim DW; Lee JW; Han K; Min WS; Park CW; Kim M; Kim YJ
Biol Blood Marrow Transplant; 2015 Mar; 21(3):460-7. PubMed ID: 25460359
[TBL] [Abstract][Full Text] [Related]
17. [Genetic diagnosis of leukemia: diagnosis of relapse and complete remission, and prediction of leukemia onset].
Sugiyama H
Rinsho Byori; 2000 Feb; 48(2):155-61. PubMed ID: 10804819
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic bone marrow transplantation (BMT) in a patient with myelodysplastic syndrome (MDS) infected by hepatitis B virus (HBV) precore mutant: favorable outcome with slow tapering of immunosuppressive agents.
Kikuchi A; Kagimoto S; Kishimoto H; Yamamoto K; Hanada R
Leukemia; 2002 Nov; 16(11):2333-5. PubMed ID: 12399982
[No Abstract] [Full Text] [Related]
19. Successful bone marrow transplantation in an adult patient with reactive hemophagocytic syndrome associated with myelodysplastic syndrome.
Karasuno T; Teshima H; Hiraoka A; Nakamura H; Masaoka T
Int J Hematol; 2000 Feb; 71(2):180-3. PubMed ID: 10745629
[TBL] [Abstract][Full Text] [Related]
20. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome.
Cilloni D; Saglio G
Acta Haematol; 2004; 112(1-2):79-84. PubMed ID: 15179007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]